|1.||Scheeren, T W: 3 articles (02/2001 - 04/2000)|
|2.||Arlt, A: 2 articles (10/2008 - 11/2007)|
|3.||Lins, M: 2 articles (10/2008 - 11/2007)|
|4.||Meissner, A: 2 articles (10/2008 - 11/2007)|
|5.||Seguin, Philippe: 2 articles (03/2008 - 02/2006)|
|6.||Gründling, M: 2 articles (11/2003 - 12/2001)|
|7.||Tugtekin, I: 2 articles (06/2001 - 03/2000)|
|8.||Radermacher, P: 2 articles (06/2001 - 03/2000)|
|9.||Geldner, G: 2 articles (06/2001 - 03/2000)|
|10.||Kiefer, P: 2 articles (06/2001 - 03/2000)|
08/11/1988 - "Dopexamine hydrochloride in chronic congestive heart failure with improved cardiac performance without increased metabolic cost."
07/01/1988 - "Failure of dopexamine to maintain haemodynamic improvement in patients with chronic heart failure."
12/01/1995 - "Intravenous dopexamine in the treatment of acute congestive heart failure: results of a multicenter, double-blind, placebo-controlled withdrawal study."
01/01/1993 - "Preliminary studies have shown that dopexamine hydrochloride can produce beneficial effects in patients with acute heart failure or with compromised left ventricular function following cardiac surgery. "
08/01/1991 - "In this multicenter, parallel design, placebo-controlled study, 45 patients with functional class III or IV chronic congestive heart failure were randomized to receive a placebo infusion or one of three different doses of dopexamine. "
|2.||Low Cardiac Output
10/01/1992 - "Titration of dopexamine, 1 to 4 micrograms/kg/min, was efficacious in producing circulatory improvement in patients with a low cardiac output after cardiac surgery."
01/01/1999 - "Dopexamine is a synthetic catecholamine used for the management of low-cardiac-output states. "
05/01/1997 - "Dopexamine has a hemodynamic profile suited to treatment of low cardiac output in anesthetized horses; however, at the dosage rate studied (4 micrograms/kg/min), its administration was associated with a number of undesirable adverse effects which could preclude its clinical use."
10/01/1993 - "Recently, dopexamine (DX), which acts via adrenergic beta 2 and dopaminergic DA1 receptors, has been introduced in the treatment of low cardiac output states. "
01/01/1993 - "In clinical practice, dopexamine hydrochloride is easy to use; the short plasma half-life (6 minutes in healthy volunteers and 11 minutes in patients with low cardiac output) allows a rapid return to pretreatment status at discontinuation of the infusion. "
02/01/1998 - "In this ovine model, gut mucosal ischemia and increased permeability occur with hypothermic CPB, but dopexamine administration during CPB, compared to placebo, neither ameliorates these intestinal derangements nor reduces post-CPB lung pathophysiology."
04/01/2001 - "A randomized study to evaluate the effect of a perioperative infusion of dopexamine on colonic mucosal ischemia after aortic surgery."
01/01/1998 - "Dopexamin, which directly influences intestinal ischemia (goal directed therapy) might be a successful treatment option, however until now no clinical study about beneficial effects of dopexamine in severely injured patients is available. "
07/01/1995 - "Gastric tonometry was used to study the possible effect of dopexamine infusion on a low calculated intramucosal pH (pHi) as a sign of splanchnic ischemia. "
08/11/1988 - "Dopexamine hydrochloride reduced the incidence and severity of arrhythmias in the early stages of ischemia: At a dose of 0.25 micrograms/kg/min, the total number of ectopic beats was reduced to 375 +/- 175, from 1,250 +/- 330 in control rats (p less than 0.05). "
|4.||Septic Shock (Toxic Shock Syndrome)
05/01/1995 - "During septic shock, however, dopexamine HCl improved oxygenation in all three organs in a dose-dependent manner."
11/01/2010 - "Dopexamine Test in septic shock with hyperlactatemia."
06/01/2001 - "Effect of dopexamine on hepatic metabolic activity in patients with septic shock."
03/01/2000 - "Effect of a dopexamine-induced increase in cardiac index on splanchnic hemodynamics in septic shock."
10/01/1998 - "A role for dopexamine hydrochloride in septic shock."
03/01/1993 - "In the present studies, the efficacy of dopexamine hydrochloride, a novel DA1-receptor and beta 2-adrenoceptor agonist in preventing deterioration of cardiovascular function in a canine model of hemorrhagic shock was investigated. "
03/01/1993 - "Evaluation of the effects of dopexamine, a novel DA1 receptor and beta 2-adrenoceptor agonist, on cardiac function and splanchnic circulation in a canine model of hemorrhagic shock."
04/01/1997 - "Dopexamine administration during crystalloid resuscitation from hemorrhagic shock was well tolerated and resulted in significant and specific, although transient, improvement in liver oxygenation."
04/01/1997 - "Dopexamine improves liver oxygenation during crystalloid resuscitation from experimental hemorrhagic shock."
04/01/1997 - "To evaluate the effects of dopexamine administration on hemodynamic variables and tissue oxygen tensions during crystalloid resuscitation from hemorrhagic shock. "
|9.||Nitroprusside (Sodium Nitroprusside)
|10.||salicylhydroxamic acid (SHAM)
|1.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)
|5.||Free Tissue Flaps